ArticleActa pharmaceutica Sinica. B2020
The construction of
Article in Acta pharmaceutica Sinica. B, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 37 citations in OpenAlex.
- Combating respiratory diseases with mucosal vaccines.Journal of virology · 2026Review
- Hypercalcemia and acute kidney injury caused by occupational inhalation of vitamin D3: a case report.Frontiers in medicine · 2026Article
- Mitochondrial-targeted and ROS-responsive nanocarrierActa pharmaceutica Sinica. B · 2023Article
- Recent progress in application of nanovaccines for enhancing mucosal immune responses.Acta pharmaceutica Sinica. B · 2023Review
- Self-assembled short peptides: Recent advances and strategies for potential pharmaceutical applications.Materials today. Bio · 2023Review
- Osthole/borneol thermosensitive gel via intranasal administration enhances intracerebral bioavailability to improve cognitive impairment in APP/PS1 transgenic mice.Frontiers in pharmacology · 2023Article
- Mucosal delivery of nanovaccine strategy against COVID-19 and its variants.Acta pharmaceutica Sinica. B · 2022Review
- Mucosal vaccine delivery: A focus on the breakthrough of specific barriers.Acta pharmaceutica Sinica. B · 2022Review
- Understanding the Phagocytosis of Particles: the Key for Rational Design of Vaccines and Therapeutics.Pharmaceutical research · 2022Review
- Intelligent lesion blood-brain barrier targeting nano-missiles for Alzheimer's disease treatment by anti-neuroinflammation and neuroprotection.Acta pharmaceutica Sinica. B · 2022Article
- A nanocleaner specifically penetrates the blood‒brain barrier at lesions to clean toxic proteins and regulate inflammation in Alzheimer's disease.Acta pharmaceutica Sinica. B · 2021Article
- Nose-to-brain delivery of borneol modified tanshinone IIA nanoparticles in prevention of cerebral ischemia/reperfusion injury.Drug delivery · 2021Article
- Forms and Methods for Interferon's Encapsulation.Pharmaceutics · 2021Review
- Intranasal delivery systems for traumatic brain injury: Advancements and perspectives.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In order to better evaluate the transport effect of nanoparticles through the nasal mucosa, an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.